GSK stops lung-cancer vaccine trial

Share this article:

GSK announced today that it has decided to stop its Phase-III MAGRIT trial of its MAGE-A3 lung-cancer vaccine. The drugmaker stated that it was unable to "identify a sub-population of gene-signature NSCLC [non-small cell lung cancer] patients that may benefit from the treatment."

Vincent Brichard, GSK SVP and head of immunotherapeutics, said, "We are extremely disappointed to learn that this trial did not have a positive outcome for the patients who participated in this trial...we hope that the data generated in this trial will advance our understanding of the science of immunotherapeutics, and ultimately towards development of new therapies."

The drugmaker said it will continue to evaluate another Phase-III trial—DERMA—to see whether a "gene signature can identify a sub-population of melanoma patients that would benefit from the same investigational MAGE-A3 immunotherapeutic."

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions